SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 200.79-0.2%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bob zagorin who wrote (28935)6/23/1999 8:01:00 PM
From: Henry Niman  Read Replies (3) of 32384
 
LGND has a very big stake in SERMs in general, although they receive no direct income from the two approved SERMs (Tamoxifen and Evista). They have alliances with several companies developing there own SERMs, including LLY's second generation compounds, PFE's Droloxifene and CP-366, and AHPs TSE424.

Not only does LGND have a direct stake in the above compounds (they have already done their share of the development with the named compounds, which are in advanced clinical trials), but they also get research funding from LLY to explore combining rexinoids with SERMs to treat breast cancer.

Since Targretin (and probably LGD1268, LGD1324, and second generation compounds), attack breast cancer by inducing the cells to differentiate and stop growing, the synergism seen with rexinoids and SERMs is probably not very dependent on the specific SERM, and the rexinoids will likely synergize with ALL of the above mentioned SERMs (as well as Idoxdifene and other SERMs being developed by others).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News